{"article_link": "https://doi.org/10.1038/s41467-023-42565-z", "data": [{"id": "data_1", "omics": "Epigenomics", "link": "https://ngdc.cncb.ac.cn/gsa-human/", "format": "BAM", "source": "Genome Sequence Archive for Human (GSA-human)", "public_id": "HRA002815"}, {"id": "data_2", "omics": "Transcriptomics", "link": "https://ngdc.cncb.ac.cn/gsa-human/", "format": "RNA-seq", "source": "Genome Sequence Archive for Human (GSA-human)", "public_id": "HRA000119", "description": "Gene expression data from RNA-seq for 89 tumors from 57 B-ALL patients (GSA-human, HRA000119)"}, {"id": "data_3", "omics": "Genomics", "link": "https://ngdc.cncb.ac.cn/gsa-human/", "format": "processed data", "source": "Genome Sequence Archive for Human (GSA-human)", "public_id": "HRA005668", "description": "Processed genomic aberrations (mutations, structural variations, CNVs) from WGS data for 32 B-ALL patients"}, {"id": "data_4", "omics": "Chromatin Immunoprecipitation Sequencing (ChIP-seq)", "link": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122989", "format": "BAM", "source": "Gene Expression Omnibus (GEO)", "public_id": "GSE122989"}, {"id": "data_5", "omics": "Chromatin Immunoprecipitation Sequencing (ChIP-seq)", "link": "https://ega-archive.org/", "format": "BAM", "source": "European Genome-phenome Archive (EGA)", "public_id": "EGAD00001002421"}, {"id": "data_6", "omics": "Transcriptomics", "link": "https://depmap.org/portal/download", "format": "Processed Data", "source": "DepMap", "public_id": "DepMap Public 21Q1"}, {"id": "data_7", "omics": "Drug Response", "link": "https://depmap.org/portal/download", "format": "Processed Data", "source": "DepMap", "public_id": "Drug sensitivity AUC (CTD^2)"}, {"id": "data_8", "omics": "Genomics", "link": "https://gdc.cancer.gov/about-data/publications#/?groups=TARGET-ALL-P2&years=&order=desc", "format": "Processed Data", "source": "TARGET", "public_id": "phs000464", "description": "TARGET cohort survival data (48 diagnosis-relapse paired B-ALL samples) for ACR-based prognostic validation"}], "analyses": [{"id": "analysis_1", "analysis_name": "Chromatin Accessibility Landscape", "analysis_data": ["data_1"], "label": null}, {"id": "analysis_2", "analysis_name": "Comparison with B-cell Progenitors", "analysis_data": ["data_1", "data_4"], "label": null}, {"id": "analysis_3", "analysis_name": "Subtype-specific Chromatin Accessibility", "analysis_data": ["data_1"], "description": "Defined by driver genomic translocations (WGS), fusions, gene expression signatures (RNA-seq), and clinical testing (karyotype/FISH). Includes 11 subtypes: hyperdiploidy, ETV6::RUNX1, TCF3::PBX1, KMT2A rearranged, BCR::ABL1, BCR::ABL1-like, ZNF384, PAX5alt, TCF3::HLF, hypodiploidy, MEF2D, and B-other."}, {"id": "analysis_4", "analysis_name": "Allele-specific Open Chromatin (ASOC) Analysis", "analysis_data": ["data_1", "data_3"], "label": null}, {"id": "analysis_5", "analysis_name": "Differential Chromatin Accessibility Between Diagnosis and Relapse", "analysis_data": ["data_1"], "label": {"status": ["diagnosis", "relapse"]}}, {"id": "analysis_6", "analysis_name": "Relapse-free Survival (RFS) Analysis", "analysis_data": ["data_1", "data_8"], "label": {"groups": ["Group A", "Group B"], "survival_metrics": ["RFS", "Event-Free Survival (EFS)", "Overall Survival (OS)"]}, "description": "Two prognostic groups (Group A and Group B) defined using RFS-related ACRs. Survival analysis includes RFS, EFS, and OS."}, {"id": "analysis_7", "analysis_name": "ACR-to-Gene Association", "analysis_data": ["data_1", "data_2"], "label": null}, {"id": "analysis_8", "analysis_name": "Drug Response Gene Enrichment Based on Drug Sensitivity AUC (CTD^2)", "analysis_data": ["data_6", "data_7"], "label": {"drugs": ["Imatinib", "Etoposide", "Dexamethasone", "Doxorubicin", "Dasatinib", "Methotrexate", "Cyclophosphamide", "Cytarabine"]}, "description": "Enrichment of drug response gene sets for Imatinib, Etoposide, Dexamethasone, Doxorubicin, Dasatinib, Methotrexate, Cyclophosphamide, and Cytarabine (p-values for drug-gene associations).", "metrics": ["p-values for drug-gene associations"]}, {"id": "analysis_9", "analysis_name": "Transcription Factor Motif Analysis", "analysis_data": ["data_1", "data_2"], "label": null, "metrics": "Transcription factor motif enrichment"}, {"id": "analysis_10", "analysis_name": "Differential Chromatin Accessibility Between Diagnosis and Relapse", "analysis_data": ["data_1"], "label": {"status": ["diagnosis", "relapse"]}}], "results": [{"analysis_id": "analysis_1", "metrics": "Number of ACRs", "value": "138,366 (median, range: 57,941â€“204,563)", "features": ["27.95% of ACRs located in Quies regions, including BCL2L11 (linked to drug resistance)", "31.30% of ACRs in Enh regions, such as the BENC enhancer cluster activating MYC", "Promoter regions of IL7R and TCL1A show increased accessibility (linked to oncogenic signaling pathways)"]}, {"analysis_id": "analysis_2", "metrics": "Overlap with B-cell Progenitor ACRs", "value": "98.57% (pre-pro B cells), 98.35% (pro B cells)", "features": ["BENC enhancer cluster with MYC activation in B-ALL"]}, {"analysis_id": "analysis_3", "metrics": "Subtype-specific ACRs", "value": "17,981 subtype-specific ACRs identified", "features": ["ETV6::RUNX1 subtype (E2F6 upregulation in cell cycle control)", "Hyperdiploidy subtype with lineage plasticity (myeloid-like gene signatures)", "KMT2A subtype showing myeloid-like gene signatures"]}, {"analysis_id": "analysis_4", "metrics": "Percentage of ASOC regions", "value": "14.39% (median), significantly less than BiOC regions (85.61%)", "features": ["rs7090445 disrupts RUNX3 binding in C-allele, potentially contributing to ARID5B downregulation and leukemogenesis", "rs13401811 located ~262 kb upstream of BCL2L11 (pro-apoptotic gene involved in ALL drug resistance)", "MECOM and HOXA9 show allele-specific transcription"]}, {"analysis_id": "analysis_5", "metrics": "Number of differential ACRs", "value": "5911 relapse-high ACRs (0.95% of total ACRs), 1423 relapse-low ACRs (0.23% of total ACRs)", "features": ["Quies regions near BCL2L11 associated with relapse", "Enh regions with MYC activation in relapsed B-ALL", "Shared ACRs contribute to general chromatin accessibility changes"]}, {"analysis_id": "analysis_6", "metrics": "Subtype-specific ACRs", "value": "98.46% (relapse-high), 99.86% (relapse-low)", "features": ["Subtype-specific ACRs reflect disease heterogeneity"]}, {"analysis_id": "analysis_7", "metrics": "ACR-gene correlations", "value": "116,307 ACR-gene correlations identified", "features": ["1259 potential target genes including BCL2L11 and cell adhesion-related genes"]}, {"analysis_id": "analysis_8", "metrics": "Enrichment of drug response genes (p-values)", "value": "Significant enrichment for Imatinib (p = 0.0029), Etoposide (p = 0.0184), Dasatinib (p = 0.0178), Doxorubicin (p = 0.0167)", "features": ["BCR::ABL1-related signaling pathway genes (Imatinib/Dasatinib)", "BCL2L11 upregulation linked to apoptosis resistance"]}, {"analysis_id": "analysis_9", "metrics": "Transcription factor motif enrichment", "features": ["E2F6 upregulation in ETV6::RUNX1 subtype (cell cycle control)", "RUNX1 and SPI1 in BCR::ABL1-like subtype (associations inferred from motif and gene expression analysis)"]}]}